Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial
- PMID: 23591255
- DOI: 10.1097/GME.0b013e318287474f
Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial
Abstract
Objective: This study aimed to explore the effects of continuous-combined estradiol 1 mg/drospirenone 2 mg (E2D) on cognitive performance in healthy, recently postmenopausal women.
Methods: A 6-month randomized, double-blind, placebo-controlled study was carried out in a university research center. Participants were 23 healthy postmenopausal women aged 49 to 55 years. Cognitive performance was assessed with a computerized cognitive battery administered to all participants on 0, 12, and 26 weeks. Functional magnetic resonance imaging was performed on 13 participants before and after treatment using tasks of verbal fluency and mental rotation.
Results: E2D was not associated with an overall effect on cognitive performance. Functional magnetic resonance imaging results showed no difference between the groups for verbal fluency or mental rotation task performance at baseline. The mental rotation task was associated with increased blood oxygen level-dependent signalling in the placebo group in both occipital lobes and in the left superior parietal lobe after 26 weeks (P < 0.05), with no changes over time seen in the treatment group. The total menopausal symptom and sexual function domain scores improved after treatment in women randomized to E2D compared with the placebo group (both P < 0.05). Similarly, systolic blood pressure, weight, and body mass index were significantly lower in women randomized to E2D at 26 weeks (P < 0.05).
Conclusions: E2D has no detrimental effect on cognitive performance in early postmenopausal women. E2D significantly improves menopausal symptoms, sexual function, systolic blood pressure, and weight.
Similar articles
-
[Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].Zhonghua Fu Chan Ke Za Zhi. 2011 May;46(5):345-9. Zhonghua Fu Chan Ke Za Zhi. 2011. PMID: 21733370 Clinical Trial. Chinese.
-
Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.Menopause. 2005 Nov-Dec;12(6):716-27. doi: 10.1097/01.gme.0000177318.24005.b1. Epub 2005 Nov 8. Menopause. 2005. PMID: 16278615 Clinical Trial.
-
A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.Menopause. 2014 Mar;21(3):227-35. doi: 10.1097/GME.0b013e31829c1431. Menopause. 2014. PMID: 23963307 Clinical Trial.
-
Drospirenone and estradiol: a new option for the postmenopausal woman.Climacteric. 2007 Feb;10 Suppl 1:3-10. doi: 10.1080/13697130601114859. Climacteric. 2007. PMID: 17364592 Review.
-
Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.Climacteric. 2005 Oct;8 Suppl 3:19-27. doi: 10.1080/13697130500330341. Climacteric. 2005. PMID: 16203652 Review.
Cited by
-
Evaluating the Cognitive Impacts of Drospirenone, a Spironolactone-Derived Progestin, Independently and in Combination With Ethinyl Estradiol in Ovariectomized Adult Rats.Front Neurosci. 2022 May 25;16:885321. doi: 10.3389/fnins.2022.885321. eCollection 2022. Front Neurosci. 2022. PMID: 35692432 Free PMC article.
-
Functional and molecular neuroimaging of menopause and hormone replacement therapy.Front Neurosci. 2014 Dec 8;8:388. doi: 10.3389/fnins.2014.00388. eCollection 2014. Front Neurosci. 2014. PMID: 25538545 Free PMC article. Review.
-
Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition.Front Endocrinol (Lausanne). 2024 Mar 4;15:1350318. doi: 10.3389/fendo.2024.1350318. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38501109 Free PMC article.
-
Ovarian steroid hormones: A long overlooked but critical contributor to brain aging and Alzheimer's disease.Front Aging Neurosci. 2022 Jul 19;14:948219. doi: 10.3389/fnagi.2022.948219. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35928995 Free PMC article. Review.
-
Enhanced Neuroactivation during Working Memory Task in Postmenopausal Women Receiving Hormone Therapy: A Coordinate-Based Meta-Analysis.Front Hum Neurosci. 2015 Feb 11;9:35. doi: 10.3389/fnhum.2015.00035. eCollection 2015. Front Hum Neurosci. 2015. PMID: 25717297 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources